Redeye briefly comments on CTEK’s new financial targets that were presented this morning ahead of to...
The major decrease in sales compared to Q1 2024 was expected.
Redeye provides a brief comment on today’s news that Freemelt has signed an agreement with a leading...
Redeye comments on GiG’s Q1-results which were largely in line with our forecast where the company s...
Redeye shares its initial impressions of NextCell’s recently announced collaboration with Fujifilm I...
Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi...
Redeye updates its view on Flexion Mobile following its Q1 2025 report, which was in line with our e...
Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m FY'25 guidance maintained, as expected Consens...
Redeye comments on today's news that Curasight's share issue was subscribed to 47%, raising DKK47m b...
Redeye believes Lagercrantz continued its stable trend and ended fiscal year 2024/2025 in a solid fa...
Redeye is satisfied with TO12's preliminary subscription rate of 71%.
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Utifrån en fortsatt svag marknad och orderingång under början av 2025 har vi sänkt våra förväntninga...
Redeye retains its positive view of Lagercrantz after a Q4 report that aligned with our projections.
Det svenska bioteknikbolaget Aptahem AB (publ) (”Aptahem” eller ”Bolaget”) utvecklar RNA-baserade lä...
